Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons dr. A.J. van der Wekken

Publicaties

An Evidence-Based Rationale for Dose De-escalation of Subcutaneous Atezolizumab

A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion–positive non–small cell lung cancer

Baseline Blood CD8+ T Cell Activation Potency Discriminates Responders from Non-Responders to Immune Checkpoint Inhibition Combined with Stereotactic Radiotherapy in Non-Small-Cell Lung Cancer

Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries

First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations

Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer

In-depth Analysis of Lorlatinib-related neurocognitive Adverse Events in Patients With Non–small-cell Lung Cancer

Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapy

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib

Prognostic Value of KRAS/TP53 Status for Overall Survival in First-Line Monoimmunotherapy and Chemoimmunotherapy Treated Patients With Nonsquamous NSCLC in the Netherlands: A Brief Report

Lees meer

Pers/media

RTV Noord journaal

Effect van pil tegen longkanker

Pil tegen longkanker 'halveert kans op overlijden' voor kleine groep patiënten

Hoop voor kleine groep longkankerpatiënten: pil per dag halveert kans op overlijden

Doelgerichte therapie bij longkanker

Actionabiliteit van on-target ALK-resistentiemutaties in niet-kleincellig longcarcinoom

Longkanker: welke vorm heb ik?

Plasma testing

Longkanker in Perspectief

Oncologie longkanker special

Lees meer